Company Overview and News
Stop missing out on important events!
The company is well-positioned to become the top player in the medical cannabis space by 2021. (15-0)
Welcome to our Weekly Cannabis Report, a reliable source for investors to receive the latest developments and critical analysis for the cannabis sector. (9-0)
Licensed marijuana producer Aphria Inc. is reducing the amount of cash it is offering for medical cannabis firm Nuuvera Inc. (6-0)
Canopy Growth offers a cannabis presence in all five announced provinces, teaming with Delta 9 for stores in Manitoba. (13-1)
Five other LPs also announced deal with local producer, Hydropothecary, scoring the largest deal with 20,000 kg. (13-0)
Feb 16 (Reuters) - Canada’s main stock index was little changed on Friday as a boost from the heavyweight energy sector was offset by a decline in gold and natural resource companies, as well as cannabis producers. (47-0)
On Thursday, Canadian security regulators and clearinghouse confirmed that cannabis companies with U.S. business will be able to continue listing, trading and clearing their shares in Canada. Aphria (OTCQB:APHQF) and other cannabis companies with business in the U.S. have avoided the worst-case scenario that could have seen them delisted from Canadian exchanges. We believe the change is positive for Aphria and removed a major overhang for the stock. (3-0)
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com (14-1)
The cannabis stocks are transitioning from the first stage of the bull market to the second stage. This means investors should change their portfolio strategy. (21-4)
The recent expensive acquisitions have really diluted the stock. This dampers potential earnings per share in the short term. (3-0)
Canadian regulators on Thursday reiterated their call for listed cannabis producers with U.S. businesses to clearly disclose risks of operating there, and warned of potential punishment if U.S. federal anti-marijuana laws are more strictly enforced. (6-0)
No one really knows the size of the Canadian cannabis market once legalized, estimates vary from $2.4 billion - $8 billion USD. (31-1)
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com (9-0)
Licensed medical marijuana producer Aphria Inc. has signed a deal to sell part of its stake in Liberty Health Sciences Inc. as it works to reduce its investments in the United States where cannabis remains illegal under federal law. (9-0)
TORONTO, Feb 5 (Reuters) - Canada’s main stock index fell to a four-month low on Monday, pressured by a drop in financial and industrial shares as a selloff in global markets weighed on investor sentiment. (26-0)
APHQF : Aphria (TSXV:APH) Analysis and Research Report
Aphria Inc., one of Canada’s lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada, Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. Aphria is committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders.
Aphria is the first public licenced medical cannabis producer to report positive cash flow from operations and the first to report positive earnings in consecutive quarters.
Pure Natures Wellness (PNW), a wholly-owned subsidiary of the Company, is licenced to produce and sell medical marijuana under the provisions of the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). PNW received its licence to produce and sell medical marijuana on November 26, 2014, followed by its licence to sell cannabis extracts on August 18, 2016. PNW’s operations are based in Leamington, ...